Evidence map›Paper›PMID 23013426›Full record

Trial reportHealth and quality of life outcomes2012

The Anti-Clot Treatment Scale (ACTS) in clinical trials: cross-cultural validation in venous thromboembolism patients.

Stefan J Cano, Donna L Lamping, Luke Bamber, Sarah Smith

2 registry-linked trialsAbstract readClinical TrialValidation Study
In one paragraph

Trial report in Health and quality of life outcomes, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 62 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00440193 phase3completednot on this map

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

TypeinterventionalSponsorBayerRan2007 to 2010Enrolled3,449ConditionsVenous ThrombosisArmsRivaroxaban (Xarelto, BAY59-7939), Enoxaparin followed by VKA
NCT02295475 phase4completednot on this mapstarted 2014, after this paper: background citation

Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome

TypeinterventionalSponsorScott C. Woller, MDRan2014 to 2022Enrolled48ConditionsAntiphospholipid Syndrome, ThrombosisArmsApixaban, Warfarin
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Renal Vein Thrombosis: A Narrative Review.Diagnostics (Basel, Switzerland) · 2026
    Review
  10. Article
  11. Article
  12. Capturing the late complications of venous thromboembolism.Research and practice in thrombosis and haemostasis · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Quality of life in oncological patients with venous thromboembolic disease.Research and practice in thrombosis and haemostasis · 2024
    Review
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Stefan J CanoDepartment of Clinical Neuroscience, Peninsula College of Medicine and Dentistry, Room N16 ITTC Building, Tamar Science Park, Davy Road, Plymouth, Devon, PL6 8BX, UK. stefan.cano@pcmd.ac.uk
Donna L Lamping
Luke Bamber
Sarah Smith

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Anti-Clot Treatment Scale (ACTS) is a 15-item patient-reported instrument of satisfaction with anticoagulant treatment. It includes a 12-item ACTS Burdens scale and a 3-item ACTS Benefits scale. Its role in clinical trials and other settings should be supported by evidence that it is both clinically meaningful and scientifically sound. The aim of the study was to evaluate the measurement performance of the ACTS (Dutch, Italian, French, German and English language versions) in patients with venous thromboembolism based on traditional psychometric methods.

methodsACTS Burdens and Benefits scale data from a large clinical trial (EINSTEIN DVT) involving 1336 people with venous thromboembolism were analysed at both the scale and item level. Five key psychometric properties were examined using traditional psychometric methods: acceptability, scaling assumptions, reliability (including internal consistency reliability, test-retest reproducibility); validity (including known groups and discriminant validity); and responsiveness. These methods of examination underpin the US Food and Drug Administration recommendations for patient-reported outcome instrument evaluation.

resultsOverall, the 12-item ACTS Burdens scale and 3-item ACTS Benefits scale met the psychometric criteria evaluated at both item and scale levels, with the exception of some relatively minor issues in the Dutch language version, which were just below reliability criteria (i.e. alpha = 0.72, test-retest intraclass correlation = 0.79). A consistent finding from item-level evaluations of aggregate endorsement frequencies and skewness suggested that response scales may be improved by reducing the number of response options from five to four.

conclusionsBoth the ACTS Burdens and ACTS Benefits scales consistently satisfied traditional reliability and validity criteria across multiple language datasets, supporting it as a clinically useful patient-reported instrument of satisfaction with anticoagulant treatment in clinical trials. TRIAL REGISTRATION NUMBER: NCT00440193.

Indexed as

Cross-Cultural ComparisonAdolescentAdultAgedAnticoagulantsFemaleHumansMaleMiddle AgedOutcome Assessment, Health CarePatient SatisfactionPractice Guidelines as TopicPsychometricsReproducibility of ResultsSurveys and QuestionnairesVenous ThromboembolismAnticoagulants

Identifiers

PMID23013426
PMCPMC3478969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.